Implementation of a Market Entry Reward within the United States

As part of a multifactorial approach to address weak incentives for innovative antimicrobial drug development, market entry rewards (MERs) are an emerging solution. Recently, the Duke-Margolis Center for Health Policy released the Priority Antimicrobial Value and Entry (PAVE) Award proposal, which c...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of law, medicine & ethics Vol. 46; no. 1_suppl; pp. 50 - 58
Main Authors Daniel, Gregory W., Schneider, Monika, Lopez, Marianne Hamilton, McClellan, Mark B.
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.06.2018
Cambridge University Press
Subjects
Antibiotics
Antimicrobial agents
Drug development
Drug resistance
Funding
Health care policy
Health technology assessment
Infections
Intellectual property
Market entry
Markets
Pathogens
Pharmaceutical industry
Proposals
Public health
Rewards
United States > US
Online AccessGet full text

Cover

More Information
Summary:As part of a multifactorial approach to address weak incentives for innovative antimicrobial drug development, market entry rewards (MERs) are an emerging solution. Recently, the Duke-Margolis Center for Health Policy released the Priority Antimicrobial Value and Entry (PAVE) Award proposal, which combines a MER with payment reforms, transitioning from volume-based to “value-based” payments for antimicrobials. Here, the PAVE Award and similar MERs are reviewed, focusing on further refinement and avenues for implementation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1073-1105
1748-720X
DOI:10.1177/1073110518782915